Segment (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Reporting Segment

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Revenue	$	15	$	34	$	30	$	50
Operating expenses:
Research and development
Technical operations	10,720		14,416		47,375		47,893
Clinical development	8,064		9,386		26,639		26,682
Non-clinical research	2,856		9,361		11,060		28,721
Facilities and technology	6,532		6,337		21,402		19,639
Total research and development expenses	28,172		39,500		106,476		122,935
General and administrative
Business support	6,369		7,238		21,402		23,804
Corporate expenses and outside services	3,316		3,637		9,954		11,112
Facilities and technology	1,002		894		3,163		2,603
Total general and administrative expenses	10,687		11,769		34,519		37,519
Other operating income, net	(1,591)		(730)		(648)		(2,796)
Impairment of long-lived assets	—		—		1,443		—
Total operating expenses	37,268		50,539		141,790		157,658
Loss from operations	(37,253)		(50,505)		(141,760)		(157,608)
Interest income, net	3,266		5,965		10,404		19,148
Other (expense) income, net	(4,859)		(43)		(2,369)		402
Impairment of other investments	—		—		—		(13,001)
Total other (loss) income, net	(1,593)		5,922		8,035		6,549
Net loss	$	(38,846)	$	(44,583)	$	(133,725)	$	(151,059)